|
1）Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994; 263: 1281-4
|
|
|
|
2）Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-6
|
|
|
|
|
|
3）Takezawa K, Okamoto I, Nishio K, et al. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res. 2011; 17: 2140-8
|
|
|
|
|
4）Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46: 1773-80
|
|
|
|
|
|
5）Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14: 4275-83
|
|
|
|
|
|
6）Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27: 4247-53
|
|
|
|
|
|
7）Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007; 67: 4408-17
|
|
|
|
|
|
8）Camidge DR, Bang YJ, Kwak EL, et al. Progression-free survival （PFS）from a phase I study of crizotinib（PF-02341066）in patients with ALK-positive non-small cell lung cancer. J Clin Oncol. 2011; 29（suppl; abstr 2501）
|
|
|
|
|
|
9）Leena G, Pasi AJ. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res. 2012; 18(14): 3737-42
|
|
|
|
|
|
10）Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-703
|
|
|
|
|
|
11）Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012; 13: 1195-201
|
|
|
|
|
|
12）Crino L, Kim D, Riely GJ, et al. Initial phase 2 results with crizotinib in advanced ALK-positive non-small cell lung cancer（NSCLC）: PROFILE 1005. J Clin Oncol. 2011; 29（suppl; abstr 7514）
|
|
|
|
|
|
13）Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010; 363: 1734-9
|
|
|
|
|
|
14）Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71: 6051-60
|
|
|
|
|
|
15）Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010; 70: 10038-43
|
|
|
|
|
|
16）Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011; 19: 679-90
|
|
|
|
|
|
17）Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011; 108: 7535-40
|
|
|
|
|
|
18）Ranee Mehra D, Camidge R, Sharma S, et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. J Clin Oncol. 2012; 30 suppl; abstr 3007
|
|
|
|
|
|
19）Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-203
|
|
|
|
|
|
20）Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15: 3143-9
|
|
|
|
|